Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Analytikerkommentar

SciBase already received first order from Austria

Af Antti LuiroHead of Nordic ER Development, Analyst
Scibase Holding

Expansion to the wider DACH region has been one of the recently updated strategic focus areas for SciBase, as the company already had a strong position in Germany to build on. The now announced order was received very quickly, only 2-3 months after the first sales representative was hired in March, and we see it as a further signal of the competitiveness and attractiveness of the Nevisense product in the skin diagnostics market.

DACH expansion is off to a promising start, but US progress remains key

Rapid commercial progress in Austria is obviously positive for the company's investment case. The company is still cash flow negative and needs to prioritize its investments in areas that contribute most to achieving cash flow neutrality. While the expansion into the broader DACH region appears to be a good move from this perspective, we believe its importance to the company's overall investment case is currently more limited. SciBase needs to make a significant jump in revenues to reach cash flow neutrality, and we believe that progress in the very large US market is the key to achieving this. SciBase reports its Q1 results tomorrow and we have commented on our expectations for the report in our Q1 preview comment.

Scibase Holding

0,32SEK29.05.2024, 18.00

SciBase Holding is a global medical technology group specialized in diagnostics and prevention in dermatology. The company develops, produces and commercializes Nevisense, a patient-centered platform that combines AI (artificial intelligence) with EIS technology to enable early detection and intervention of skin cancer and other skin diseases. Nevisense is based on over 20 years of research at Karolinska Institutet, the headquarters are in Stockholm.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team